Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5523316 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2EPHX2EPHX1TSHR | |
| SCHEMBL20196820 | 0.85 | USP2 (0.41) | USP2SMN1; SMN2EPHX2EPHX1DDB1 | |
| SCHEMBL3031720 | 0.80 | USP2 (0.46) | USP2SMN1; SMN2EPHX2EPHX1TSHR | |
| SCHEMBL31566967 | 0.79 | PIK3R1 (0.41) | USP2SMN1; SMN2EPHX2DDB1CRBN | |
| SCHEMBL31094820 | 0.78 | USP2 (0.47) | USP2SMN1; SMN2EPHX2EPHX1DDB1 | |
| SCHEMBL20621851 | 0.78 | HPGD (0.43) | USP2SMN1; SMN2EPHX2EPHX1TSHR | |
| SCHEMBL19226693 | 0.77 | USP2 (0.44) | USP2SMN1; SMN2EPHX2EPHX1TSHR | |
| SCHEMBL25363246 | 0.77 | USP2 (0.46) | USP2SMN1; SMN2EPHX2EPHX1DDB1 | |
| SCHEMBL20869150 | 0.76 | SMN1; SMN2 (0.38) | USP2SMN1; SMN2EPHX2EPHX1TSHR | |
| SCHEMBL25361748 | 0.75 | USP2 (0.45) | USP2SMN1; SMN2EPHX2EPHX1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205610-B1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-8293735-B2 | Thienopyrimidine derivatives as P13K inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | US | disclosed |
| EP-2205610-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009053715-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | USP2 3145/4885SMN1; SMN2 2967/4885EPHX2 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.